Oncology
 |
|
21 january 2020 18:00:28 |
| Therapies after first-line afatinib in patients with EGFRm+ NSCLC in Japan: retrospective analysis of LUX-Lung 3 (Future Oncology) |
|
Tweet Future Oncology, Volume 16, Issue 4, Page 49-60, February 2020. |
| 158 viewsCategory: Oncology |
 Understanding the adverse event experience in the S-TRAC adjuvant trial of sunitinib for high-risk renal cell carcinoma (Future Oncology)Systematic review of neurotrophic tropomyosin-related kinase inhibition as a tumor-agnostic management strategy (Future Oncology) 
|
| blog comments powered by Disqus |
MyJournals.org
The latest issues of all your favorite science journals on one page
The latest issues of all your favorite science journals on one page
